Novartis gets FDA approval for expanded use of Tasigna

06/17/2010 | Wall Street Journal, The

The FDA authorized Novartis to promote Tasigna as a treatment for adults in earlier stages of Philadelphia chromosome-positive chronic myeloid leukemia. The drug was approved in October 2007 for patients whose disease had progressed or who failed to respond to other treatments, including Novartis' Gleevec.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Alcon
Fort Worth, TX